- Home
- EDIT vs CHEC Comparison
EDIT vs CHEC Comparison
Compare EDIT & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | CHEC |
|---|---|---|
| Founded | 2013 | 2024 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 174.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | CHEC |
|---|---|---|
| Price | $1.73 | $10.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 16.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $9.91 |
| 52 Week High | $4.54 | $10.56 |
Technical Indicators
Market Signals| Indicator | EDIT | CHEC |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 51.33 |
| Support Level | $1.67 | $10.02 |
| Resistance Level | $1.83 | $10.04 |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 15.22 | 37.50 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.